Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis. J of Skin [Internet]. 2020 Sep. 2 [cited 2025 Jun. 9];4(5):s43. Available from: https://skin.dermsquared.com/skin/article/view/992